Registered number
09904272
ONCOSOL LIMITED
Filleted Accounts
31 March 2024
ONCOSOL LIMITED
Registered number: 09904272
Balance Sheet
as at 31 March 2024
Notes 2024 2023
£ £
Current assets
Debtors 4 18,128 112,991
Cash at bank and in hand 16,970 232
35,098 113,223
Creditors: amounts falling due within one year 5 (88,379) (137,812)
Net current liabilities (53,281) (24,589)
Net liabilities (53,281) (24,589)
Capital and reserves
Called up share capital 100 100
Profit and loss account (53,381) (24,689)
Shareholders' funds (53,281) (24,589)
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
Dr Amrut Naik
Director
Approved by the board on 19 February 2025
ONCOSOL LIMITED
Notes to the Accounts
for the period from 7 November 2023 to 31 March 2024
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Changes in the accounting reference dates
During the year, the company changed its accounting reference date from 6 Novemeber to 31 March. As a result, the current financial statements cover a 5-month period from 7 November 2023 to 31 March 2024. The comparative figures cover a 10-month period from 1 January 2023 to 6 November 2023.
Going concern
The financial statements have been prepared on a going concern basis. The company has a net liability position as of the balance sheet date. However, the directors have received a letter of support from the parent company, which confirms that the parent will provide the necessary financial support to enable the company to meet its obligations as they fall due for at least the next 12 months from the date of approval of these financial statements. Based on this support, the directors believe that it is appropriate to prepare the financial statements on a going concern basis.
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Research and development
Research and development expenditure is written off to the profit and loss account in the year in which it is incurred.
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
2 Audit information
The audit report is unqualified.
Senior statutory auditor: Devender Arora ACA
Firm: The Corporate Practice Limited
Date of audit report: 19 February 2025
3 Employees 2024 2023
Number Number
Average number of persons employed by the company 0 0
4 Debtors 2024 2023
£ £
Deferred tax asset 17,708 -
Other debtors 420 112,991
18,128 112,991
5 Creditors: amounts falling due within one year 2024 2023
£ £
Trade creditors 44,138 23,548
Amounts owed to group undertakings and undertakings 36,524 -
Other creditors 7,717 114,264
88,379 137,812
6 Events after the reporting date
The directors confirm that there have been no significant events occurring after the balance sheet date that would require adjustment or disclosure in the financial statements.
7 Related party transactions 2024 2023
£ £
L M Manufacturing Limited
Common director
Included within debtors is an amount receivable of: - 76,560
Included within creditors is an amount payable of: 12,377 -
Liqmeds Lifecare Limited
Common director
Included within creditors is an amount payable of: 16,223 104,085
During the year the company purchased services from Liqmeds Lifecare Limited of: - 85,660
Liqmeds Worldwide Limited
Common director
Included within creditors is an amount payable of: 1,787 1,868
Zydus Pharmaceuticals UK Limited
Common director
Included within creditors is an amount payable to Zydus Pharmaceuticals UK Limited of: 1,768 1,768
Medsolutions (Europe ) Limited
Common director
Included within creditors is an amount receivable from Medsolutions (Europe) Limited of: 4,318 -
Mohammad Arsalaan Khan
Director of the company
Included within credtiors is an amount payable to
Mr Mohammad Arsalaan Khan of:
1,767 1,767
8 Controlling party
The company is under joint control of Liqmeds Lifecare Limited and Koana Healthcare Limited.
However, the ultimate controlling party is Zydus Pharmaceuticals UK Limited by the virtue of operational controls.
9 Other information
ONCOSOL LIMITED is a private company limited by shares and incorporated in England. Its registered office is:
Sandretto Building
Cavalry Hill Industrial Park
Weedon
Northampton
ONCOSOL LIMITED 09904272 false 2023-11-07 2024-03-31 2024-03-31 VT Final Accounts April 2024 Dr Amrut Naik No description of principal activity 09904272 2023-01-01 2023-11-06 09904272 core:WithinOneYear 2023-11-06 09904272 core:ShareCapital 2023-11-06 09904272 core:RetainedEarningsAccumulatedLosses 2023-11-06 09904272 2023-11-07 2024-03-31 09904272 bus:PrivateLimitedCompanyLtd 2023-11-07 2024-03-31 09904272 bus:Audited 2023-11-07 2024-03-31 09904272 bus:Director40 2023-11-07 2024-03-31 09904272 1 2023-11-07 2024-03-31 09904272 2 2023-11-07 2024-03-31 09904272 1 2023-11-07 2024-03-31 09904272 countries:England 2023-11-07 2024-03-31 09904272 bus:FRS102 2023-11-07 2024-03-31 09904272 bus:FilletedAccounts 2023-11-07 2024-03-31 09904272 bus:SmallCompaniesRegimeForAccounts 2023-11-07 2024-03-31 09904272 2024-03-31 09904272 core:WithinOneYear 2024-03-31 09904272 core:ShareCapital 2024-03-31 09904272 core:RetainedEarningsAccumulatedLosses 2024-03-31 09904272 2023-11-06 iso4217:GBP xbrli:pure